
Metsera (MTSR) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
0
Operating Income
-65.8M
Net Income
-76.6M
EPS (Diluted)
$-1.03
Balance Sheet Metrics
Total Assets
690.7M
Total Liabilities
185.3M
Shareholders Equity
505.4M
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
-67.7M
Free Cash Flow
-54.3M
Revenue & Profitability Trend
Metsera Income Statement From 2023 to 2024
Metric | 2024 | 2023 |
---|---|---|
Revenue | 0 | 0 |
Cost of Goods Sold | - | - |
Gross Profit | - | - |
Gross Margin % | 0.0% | 0.0% |
Operating Expenses | ||
Research & Development | 107.5M | 15.6M |
Selling, General & Administrative | 26.8M | 15.0M |
Other Operating Expenses | - | - |
Total Operating Expenses | 134.3M | 30.6M |
Operating Income | -134.3M | -30.6M |
Operating Margin % | 0.0% | 0.0% |
Non-Operating Items | ||
Interest Income | 6.2M | 1.9M |
Interest Expense | 223.0K | 0 |
Other Non-Operating Income | -90.1M | -18.5M |
Pre-tax Income | -218.5M | -47.2M |
Income Tax | -9.3M | 0 |
Effective Tax Rate % | 0.0% | 0.0% |
Net Income | -209.1M | -47.2M |
Net Margin % | 0.0% | 0.0% |
Key Metrics | ||
EBITDA | -128.1M | -34.1M |
EPS (Basic) | $-2.03 | $-0.95 |
EPS (Diluted) | $-2.03 | $-0.95 |
Basic Shares Outstanding | 103035182 | 49944659 |
Diluted Shares Outstanding | 103035182 | 49944659 |
Income Statement Trend
Metsera Balance Sheet From 2022 to 2024
Metric | 2024 | 2023 | 2022 |
---|---|---|---|
Assets | |||
Current Assets | |||
Cash & Equivalents | 352.4M | 75.2M | 15.0M |
Short-term Investments | - | - | - |
Accounts Receivable | - | - | - |
Inventory | - | - | - |
Other Current Assets | 1.6M | 761.0K | - |
Total Current Assets | 359.1M | 76.8M | 15.0M |
Non-Current Assets | |||
Property, Plant & Equipment | 1.4M | 27.0K | - |
Goodwill | 112.3M | 113.8M | 0 |
Intangible Assets | 68.5M | 69.4M | - |
Long-term Investments | - | - | - |
Other Non-Current Assets | - | 410.0K | - |
Total Non-Current Assets | 91.9M | 92.0M | 0 |
Total Assets | 451.0M | 168.8M | 15.0M |
Liabilities | |||
Current Liabilities | |||
Accounts Payable | 20.8M | 2.7M | 0 |
Short-term Debt | 9.1M | - | - |
Current Portion of Long-term Debt | - | - | - |
Other Current Liabilities | 19.1M | 13.3M | - |
Total Current Liabilities | 67.3M | 20.2M | 613.0K |
Non-Current Liabilities | |||
Long-term Debt | 701.0K | 0 | 15.2M |
Deferred Tax Liabilities | 7.8M | 17.7M | 0 |
Other Non-Current Liabilities | 87.8M | 32.5M | - |
Total Non-Current Liabilities | 96.3M | 50.2M | 15.2M |
Total Liabilities | 163.6M | 70.3M | 15.8M |
Equity | |||
Common Stock | 0 | 0 | 0 |
Retained Earnings | -257.1M | -48.0M | -813.0K |
Treasury Stock | - | - | - |
Other Equity | - | - | - |
Total Shareholders Equity | 287.4M | 98.5M | -813.0K |
Key Metrics | |||
Total Debt | 9.8M | 0 | 15.2M |
Working Capital | 291.8M | 56.6M | 14.4M |
Balance Sheet Composition
Metsera Cash Flow Statement From 2023 to 2024
Metric | 2024 | 2023 |
---|---|---|
Operating Activities | ||
Net Income | -209.1M | -47.2M |
Depreciation & Amortization | 14.0K | 2.0K |
Stock-Based Compensation | 2.4M | 85.0K |
Working Capital Changes | 16.5M | 2.6M |
Operating Cash Flow | -111.8M | -42.3M |
Investing Activities | ||
Capital Expenditures | -43.0K | -29.0K |
Acquisitions | 0 | -28.2M |
Investment Purchases | - | - |
Investment Sales | - | - |
Investing Cash Flow | -43.0K | -28.2M |
Financing Activities | ||
Share Repurchases | - | - |
Dividends Paid | - | - |
Debt Issuance | - | 0 |
Debt Repayment | - | - |
Financing Cash Flow | 378.2M | 123.7M |
Free Cash Flow | -100.1M | -35.4M |
Net Change in Cash | 266.3M | 53.2M |
Cash Flow Trend
Metsera Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-15.72
Forward P/E
-9.61
Price to Book
7.56
PEG Ratio
-0.24
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-72.78%
Return on Assets
-46.37%
Financial Health
Current Ratio
5.26
Debt to Equity
0.24
Per Share Data
EPS (TTM)
$-2.93
Book Value per Share
$4.28
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
mtsr | 3.4B | -15.72 | 7.56 | -72.78% | 0.00% | 0.24 |
Vertex | 100.2B | 27.77 | 5.83 | 22.77% | 31.86% | 8.89 |
Regeneron | 62.9B | 14.95 | 2.06 | 15.34% | 31.37% | 9.04 |
BridgeBio Pharma | 9.4B | -16.98 | -5.24 | 36.76% | 98.25% | -1.04 |
Madrigal | 8.5B | -17.67 | 12.12 | -36.30% | -54.68% | 17.81 |
Blueprint Medicines | 8.4B | -120.99 | 24.43 | -47.71% | -27.70% | 208.50 |
Financial data is updated regularly. All figures are in the company's reporting currency.